Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs

Oncotarget

Volumn 6, Issue 36, 2015, Pages 38504-38516

  Zhou, Ming ^a   Wang, Lei ^a   Zhou, Songqin ^a   Wang, Zhao ^a   Ruan, Juncheng ^a   Tang, Lijun ^c   Jia, Ziming ^c   Cui, Min ^a   Zhao, Ling ^a   Fu, Zhen F ^a,b  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b UNIVERSITY OF GEORGIA   (United States)

^c Hubei Academy of Preventive Medicine Sciences   (China)

Author keywords

Dog; GM CSF; Immune response; Immunity; Immunology and Microbiology Section; Oral vaccine; Rabies; Recombinant rabies virus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; RABIES VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DOG; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNOHISTOCHEMISTRY; LD50; NONHUMAN; RABIES; RABIES VIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TONSIL; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; DOG DISEASES; GENETICS; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; RANDOMIZATION; VETERINARY; VIROLOGY;

ADMINISTRATION, ORAL; ANIMALS; DOG DISEASES; DOGS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RABIES; RABIES VACCINES; RABIES VIRUS; RANDOM ALLOCATION; VACCINES, SYNTHETIC;

EID: 84948807276     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5904     Document Type: Article

References (59)

1. Fooks AR, Banyard AC, Horton DL, Johnson N, McElhinney LM and Jackson AC. Current status of rabies and prospects for elimination. Lancet. 2014; 384:1389-1399.
2. World Health O. WHO Expert Consultation on Rabies. Second report. World Health Organization technical report series. 2013; :1-139, back cover.
3. World Health O. Rabies vaccines: WHO position paper. Weekly Epidemiological Record. 2010; 85:309-320.
4. Hu R, Tang Q, Tang J and Fooks AR. Rabies in China: an update. Vector borne and zoonotic diseases. 2009; 9:1-12.
5. Coleman PG and Dye C. Immunization coverage required to prevent outbreaks of dog rabies. Vaccine. 1996; 14:185-186.
6. Massei G and Miller LA. Nonsurgical fertility control for managing free-roaming dog populations: a review of products and criteria for field applications. Theriogenology. 2013; 80:829-838.
7. Davlin SL and Vonville HM. Canine rabies vaccination and domestic dog population characteristics in the developing world: a systematic review. Vaccine. 2012; 30:3492-3502.
8. Sudarshan MK, Mahendra BJ and Narayan DH. A community survey of dog bites, anti-rabies treatment, rabies and dog population management in Bangalore city. The Journal of communicable diseases. 2001; 33:245-251.
9. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, Meslin F, Lobo D, Ravikumar K and Gangaboraiah. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2007; 11:29-35.
10. Song M, Tang Q, Rayner S, Tao XY, Li H, Guo ZY, Shen XX, Jiao WT, Fang W, Wang J and Liang GD. Human rabies surveillance and control in China, 2005-2012. BMC Infect Dis. 2014; 14:212.
11. Zhu WY and Liang GD. Current status of canine rabies in China. Biomedical and environmental sciences: BES. 2012; 25:602-605.
12. Kasempimolporn S, Sichanasai B, Saengseesom W, Puempumpanich S, Chatraporn S and Sitprija V. Prevalence of rabies virus infection and rabies antibody in stray dogs: a survey in Bangkok, Thailand. Preventive veterinary medicine. 2007; 78:325-332.
13. MacInnes CD, Smith SM, Tinline RR, Ayers NR, Bachmann P, Ball DG, Calder LA, Crosgrey SJ, Fielding C, Hauschildt P, Honig JM, Johnston DH, Lawson KF, Nunan CP, Pedde MA, Pond B, et al. Elimination of rabies from red foxes in eastern Ontario. Journal of wildlife diseases. 2001; 37:119-132.
14. Robbins AH, Borden MD, Windmiller BS, Niezgoda M, Marcus LC, O'Brien SM, Kreindel SM, McGuill MW, DeMaria A, Jr., Rupprecht CE and Rowell S. Prevention of the spread of rabies to wildlife by oral vaccination of raccoons in Massachusetts. Journal of the American Veterinary Medical Association. 1998; 213:1407-1412.
15. Fearneyhough MG, Wilson PJ, Clark KA, Smith DR, Johnston DH, Hicks BN and Moore GM. Results of an oral rabies vaccination program for coyotes. Journal of the American Veterinary Medical Association. 1998; 212:498-502.
16. Stohr K and Meslin FM. Progress and setbacks in the oral immunisation of foxes against rabies in Europe. The Veterinary record. 1996; 139:32-35.
17. Aubert MF, Masson E, Artois M and Barrat J. Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France. Current topics in microbiology and immunology. 1994; 187:219-243.
18. Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, Wiktor T, Koprowski H and Lecocq JP. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984; 312:163-166.
19. Roscoe DE, Holste WC, Sorhage FE, Campbell C, Niezgoda M, Buchannan R, Diehl D, Niu HS and Rupprecht CE. Efficacy of an oral vaccinia-rabies glycoprotein recombinant vaccine in controlling epidemic raccoon rabies in New Jersey. Journal of wildlife diseases. 1998; 34:752-763.
20. Hanlon CA, Niezgoda M, Hamir AN, Schumacher C, Koprowski H and Rupprecht CE. First North American field release of a vaccinia-rabies glycoprotein recombinant virus. Journal of wildlife diseases. 1998; 34:228-239.
21. Brochier B, Kieny MP, Costy F, Coppens P, Bauduin B, Lecocq JP, Languet B, Chappuis G, Desmettre P, Afiademanyo K and et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991; 354:520-522.
22. Centers for Disease C and Prevention. Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morbidity and mortality weekly report. 2009; 58:1204-1207.
23. Rupprecht CE, Blass L, Smith K, Orciari LA, Niezgoda M, Whitfield SG, Gibbons RV, Guerra M and Hanlon CA. Human infection due to recombinant vaccinia-rabies glycoprotein virus. The New England journal of medicine. 2001; 345:582-586.
24. Seif I, Coulon P, Rollin PE and Flamand A. Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. Journal of virology. 1985; 53:926-934.
25. Dietzschold B, Wunner WH, Wiktor TJ, Lopes AD, Lafon M, Smith CL and Koprowski H. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proceedings of the National Academy of Sciences of the United States of America. 1983; 80:70-74.
26. Orciari LA, Niezgoda M, Hanlon CA, Shaddock JH, Sanderlin DW, Yager PA and Rupprecht CE. Rapid clearance of SAG-2 rabies virus from dogs after oral vaccination. Vaccine. 2001; 19:4511-4518.
27. Bingham J, Schumacher CL, Hill FW and Aubert A. Efficacy of SAG-2 oral rabies vaccine in two species of jackal (Canis adustus and Canis mesomelas). Vaccine. 1999; 17:551-558.
28. Bingham J, Schumacher CL, Aubert MF, Hill FW and Aubert A. Innocuity studies of SAG-2 oral rabies vaccine in various Zimbabwean wild non-target species. Vaccine. 1997; 15:937-943.
29. Schumacher CL, Coulon P, Lafay F, Benejean J, Aubert MF, Barrat J, Aubert A and Flamand A. SAG-2 oral rabies vaccine. The Onderstepoort journal of veterinary research. 1993; 60:459-462.
30. Cliquet F, Gurbuxani JP, Pradhan HK, Pattnaik B, Patil SS, Regnault A, Begouen H, Guiot AL, Sood R, Mahl P, Singh R, Meslin FX, Picard E, Aubert MF and Barrat J. The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs. Vaccine. 2007; 25:3409-3418.
31. Fekadu M, Nesby SL, Shaddock JH, Schumacher CL, Linhart SB and Sanderlin DW. Immunogenicity, efficacy and safety of an oral rabies vaccine (SAG-2) in dogs. Vaccine. 1996; 14:465-468.
32. Rupprecht CE, Hanlon CA, Blanton J, Manangan J, Morrill P, Murphy S, Niezgoda M, Orciari LA, Schumacher CL and Dietzschold B. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus research. 2005; 111:101-105.
33. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ and Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology. 2006; 356:147-154.
34. Vos A, Neubert A, Pommerening E, Muller T, Dohner L, Neubert L and Hughes K. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. The Journal of general virology. 2001; 82:2191-2197.
35. Zhang S, Liu Y, Fooks AR, Zhang F and Hu R. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine. 2008; 26:345-350.
36. Amann R, Rohde J, Wulle U, Conlee D, Raue R, Martinon O and Rziha HJ. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. Journal of virology. 2013; 87:1618-1630.
37. Yuan Z, Zhang S, Liu Y, Zhang F, Fooks AR, Li Q and Hu R. A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine. 2008; 26:1314-1321.
38. Zhou M, Zhang G, Ren G, Gnanadurai CW, Li Z, Chai Q, Yang Y, Leyson CM, Wu W, Cui M and Fu ZF. Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations. PloS one. 2013; 8:e63384.
39. Wen Y, Wang H, Wu H, Yang F, Tripp RA, Hogan RJ and Fu ZF. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. Journal of virology. 2011; 85:1634-1644.
40. Zhao L, Toriumi H, Wang H, Kuang Y, Guo X, Morimoto K and Fu ZF. Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. Journal of virology. 2010; 84:9642-9648.
41. Zhao L, Toriumi H, Kuang Y, Chen H and Fu ZF. The roles of chemokines in rabies virus infection: overexpression may not always be beneficial. Journal of virology. 2009; 83:11808-11818.
42. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, Dietzschold B and Schnell MJ. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. Journal of virology. 2005; 79:14141-14148.
43. Shanafelt AB and Kastelein RA. Identification of critical regions in mouse granulocyte-macrophage colony-stimulating factor by scanning-deletion analysis. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86:4872-4876.
44. Zhan Y, Xu Y and Lew AM. The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Molecular immunology. 2012; 52:30-37.
45. Wanjalla CN, Goldstein EF, Wirblich C and Schnell MJ. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology. 2012; 426:120-133.
46. Ramsburg E, Publicover J, Buonocore L, Poholek A, Robek M, Palin A and Rose JK. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. Journal of virology. 2005; 79:15043-15053.
47. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H and de Gast GC. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:8978-8991.
48. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL and Yeo CJ. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19:145-156.
49. Kass E, Parker J, Schlom J and Greiner JW. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine. 2000; 12:960-971.
50. Mastrangelo MJ, Maguire HC, Jr., Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer gene therapy. 1999; 6:409-422.
51. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90:3539-3543.
52. Yu L, Zhou Y, Jiang Y, Tong W, Yang S, Gao F, Wang K, Li L, Xia T, Cheng Q and Tong G. Construction and in vitro evaluation of a recombinant live attenuated PRRSV expressing GM-CSF. Virology journal. 2014; 11:201.
53. Becker Y. Immunological and regulatory functions of uninfected and virus infected immature and mature subtypes of dendritic cells--a review. Virus genes. 2003; 26:119-130.
54. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245-252.
55. Monaco F, Franchi PM and Lelli R. Studies on an inactivated vaccine against rabies virus in domestic animals. Developments in biologicals. 2006; 125:233-239.
56. Blancou J, Kieny MP, Lathe R, Lecocq JP, Pastoret PP, Soulebot JP and Desmettre P. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature. 1986; 322:373-375.
57. Cho KA, Kim JY, Kim HS, Ryu KH and Woo SY. Tonsil-derived mesenchymal progenitor cells acquire a follicular dendritic cell phenotype under cytokine stimulation. Cytokine. 2012; 59:211-214.
58. Zhu Y, Zhang G, Shao M, Lei Y, Jiang Y and Tu C. An outbreak of sheep rabies in Shanxi province, China. Epidemiology and infection. 2011; 139:1453-1456.
59. Reed LJ and Muench H. A simple method of estimating fifty percent end points. Am J Hyg. 1938; 27:493-497.